Genetic Technology News

摘要

Recombinant Polyclonal Starts ITP Clinical Trial; Zyomyx and Imperial College Test for HIV Status; GTN Strategic Partners; Some Important Patents for You To Check; DEBIOPHARM TNFA VACCINE FOR INFLAMMATION: Tumor necrosis factor alpha (TNFa) is a powerful cytokine involved in the immune response to protect the body. It also plays a harmful role in inflammation, which occurs when the immune system attacks the patient's own tissues. Blocking TNFa is an important approach to developing effective treatments for autoimmune diseases. Debiopharm SA has found that Debio-0512, a vaccine it is developing against TNFa, inhibits inflammatory processes in animal models of acute and chronic inflammation. These results show that the candidate has potential for treating autoimmune diseases, such as rheumatoid arthritis and Crohn's disease.